NOVAVAX INC Debt Securities, Available-for-sale
NOVAVAX INC (NVAX) had Debt Securities, Available-for-sale of $2.25 million as of 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2021-05-10
- 2021-03-31: Debt Securities, Available-for-sale $2.25M.
- 2020-12-31: Debt Securities, Available-for-sale $157.65M.
- 2020-09-30: Debt Securities, Available-for-sale $169.86M.
- 2020-06-30: Debt Securities, Available-for-sale $77.90M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2021-03-31 | $2.25M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $157.65M 10-Q · filed 2021-05-10 |
| 2020-09-30 | $169.86M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $77.90M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $57.47M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2018-12-31 | $21.98M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |